ACHL Stock Overview
A biopharmaceutical company, develops precision T cell therapies to treat solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Achilles Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.07 |
| 52 Week High | US$1.76 |
| 52 Week Low | US$0.63 |
| Beta | 1.34 |
| 11 Month Change | 8.08% |
| 3 Month Change | 45.30% |
| 1 Year Change | 25.87% |
| 33 Year Change | -78.21% |
| 5 Year Change | n/a |
| Change since IPO | -93.53% |
Recent News & Updates
Recent updates
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?
Sep 20
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Feb 26Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 13Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Jul 19Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Mar 11Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 18Achilles-led group gets €4M funding for personalized cell therapy manufacturing
Jul 21Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?
Apr 13Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans
Dec 27Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Sep 09Shareholder Returns
| ACHL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 2.0% |
| 1Y | 25.9% | 18.0% | 32.4% |
Return vs Industry: ACHL exceeded the US Biotechs industry which returned 18% over the past year.
Return vs Market: ACHL underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| ACHL volatility | |
|---|---|
| ACHL Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACHL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ACHL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 210 | Iraj Ali | www.achillestx.com |
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Achilles Therapeutics plc Fundamentals Summary
| ACHL fundamental statistics | |
|---|---|
| Market cap | US$44.04m |
| Earnings (TTM) | -US$66.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs ACHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACHL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$66.88m |
| Earnings | -US$66.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACHL perform over the long term?
See historical performance and comparison